In a large retrospective study drawn from Beijing, colchicine, a drug long valued for calming inflammation, was not found to accompany fewer heart and blood-vessel events among Chinese adults who had just begun urate-lowering treatment. The question is an old one: chronic inflammation is thought to quietly drive atherosclerosis, and the evidence on whether colchicine can shield the heart has been mixed, largely because most of it was gathered in Western populations. This work offers one more piece of that unfinished picture, showing no clear benefit in this cohort without claiming to settle th
Colchicine Shows No Cardiovascular Benefit in Chinese Adults Starting Urate-Lowering Therapy
The two groups looked essentially the same, and the interval spans no effect.
Mark
Start with the headline finding. What did the Beijing team actually see?
Mimi
Among 285,727 adults starting urate-lowering therapy, colchicine users and non-users had nearly identical cardiovascular event rates: 1.62 versus 1.59 per 100 person-years.
Mark
And the hazard ratio?
Mimi
1.01, with an interval of 0.91 to 1.12. That's no difference, not a hint of benefit.
Luke
Worth saying the groups were very unequal. Only 6,157 took colchicine, against 279,570 who didn't.
Mimi
Right, and they differed. Users averaged about 49 years old and were 18.4% female; non-users averaged 53.5 and were 34% female.
Mark
Why does the population matter?
Mimi
Prior colchicine research has mostly been in Western populations, so this fills a gap.
Luke
But it's retrospective and observational. Confounding can't be fully ruled out, and the source doesn't say how it was adjusted for.
Mark
What about younger-onset disease?
Mimi
For events at 65 or younger, the hazard ratio was 0.96, interval 0.82 to 1.12. Still no clear signal.
Luke
So the fair reading is: no association found here. It doesn't prove colchicine does nothing; that would take randomized trials.
Le Pouls
- Nearly 286,000 Chinese adults starting urate-lowering therapy formed the ground for a question that has long divided the evidence on colchicine and heart protection.
- Colchicine users and non-users experienced cardiovascular events at almost identical rates, with a hazard ratio of 1.01 and no sign of a protective edge.
- Even among people whose heart disease appeared at age 65 or younger, the two groups looked alike, with a hazard ratio of 0.96.
- The design is observational and retrospective, and the groups differed in age and sex, so confounding cannot be fully ruled out.
- The finding is landing as a careful signal rather than a verdict, with randomized trials in diverse populations seen as the path to a firmer answer.
In a large retrospective study drawn from Beijing, colchicine, a drug long valued for calming inflammation, was not found to accompany fewer heart and blood-vessel events among Chinese adults who had just begun urate-lowering treatment. The question is an old one: chronic inflammation is thought to quietly drive atherosclerosis, and the evidence on whether colchicine can shield the heart has been mixed, largely because most of it was gathered in Western populations. This work offers one more piece of that unfinished picture, showing no clear benefit in this cohort without claiming to settle the matter.
A large retrospective study from Beijing has taken a closer look at colchicine, a drug better known for its anti-inflammatory action, and whether it protects the heart in people who begin treatment for high uric acid. The research, led by Yang R and colleagues and published in BMC Medicine in early November 2026, follows a long-running question. Inflammation is widely seen as a driver of cardiovascular disease, and colchicine has been studied as a way to temper it, yet results have been inconsistent, and most prior work came from Western countries.
The researchers examined 285,727 adults in Beijing who started urate-lowering therapy between 2010 and 2017. Of these, 6,157 had been prescribed colchicine and the rest had not. The two groups were not alike: colchicine users were younger on average and far less likely to be female, a difference the authors had to keep in view.
When the outcomes were compared, the picture was flat. Major cardiovascular events occurred at nearly the same rate in both groups, with a hazard ratio of 1.01. Among those whose disease appeared at age 65 or younger, the results were similar, with no clear protective signal.
The study does not show that colchicine causes harm, and it does not close the broader debate. What it does show is that, in this large Chinese cohort, colchicine use alongside starting urate-lowering therapy was not accompanied by fewer cardiovascular events. A definitive answer would require randomized trials across more diverse populations.
A large retrospective study out of Beijing has found that colchicine, a drug long studied for its anti-inflammatory effects, was not linked to fewer cardiovascular events in Chinese adults who had just started urate-lowering therapy. The paper, led by Yang R and colleagues, was published in BMC Medicine on November 3, 2026, ahead of print.
The question behind it is a familiar one. Atherosclerotic cardiovascular disease is the leading cause of death worldwide, and chronic inflammation is considered a significant driver of that risk. Colchicine has been explored as a way to dampen that inflammation, but the evidence on whether it actually protects the heart has been conflicting. Most of that work, the authors note, has been done in Western populations, leaving a gap for Chinese patients.
To address it, the researchers drew on 285,727 adults in Beijing who began urate-lowering therapy between 2010 and 2017. Of these, 6,157 were exposed to colchicine and 279,570 were not. The two groups differed in makeup. Colchicine users had a mean age of 48.9 years (standard deviation 14.7) and were 18.4% female. Those not exposed averaged 53.5 years (standard deviation 15.4) and were 34% female.
The outcome was major cardiovascular events. Among colchicine users, the incidence rate was 1.62 per 100 person-years. Among non-users it was 1.59 per 100 person-years. The resulting hazard ratio was 1.01, with a 95% confidence interval of 0.91 to 1.12. In plain terms, the two groups looked essentially the same, and the interval spans no effect.
The team also looked specifically at early cardiovascular disease, defined as onset at age 65 or younger. There too, the groups were similar, with a hazard ratio of 0.96 and a confidence interval of 0.82 to 1.12. Again, no clear protective signal emerged.
The study carries an Evidence Rating of Level 2 (Good) from the summarizing publication, 2 Minute Medicine. Its design sets limits, however. It is observational and retrospective, so it cannot fully rule out confounding, and the groups were not identical in age or sex to begin with. The exposed group was smaller, younger, and more heavily male.
What the result does and does not say is worth keeping straight. It does not show that colchicine is harmful, and it does not settle the broader debate. It says that in this large Beijing cohort, taking colchicine alongside the start of urate-lowering therapy did not accompany fewer cardiovascular events. Settling colchicine's role would require randomized trials in more diverse populations.
Citations marquantes
Among Chinese patients starting urate-lowering therapy, colchicine use was not associated with a reduction in cardiovascular events.— Yang R and colleagues, BMC Medicine (paraphrased)
Envie de l'histoire complète ?
Lire l'original sur 2 Minute Medicine ↗